Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Petróleo Brasileiro SA (PBR) Price & Performance

Crispr Therapeutics AGTrade
Petróleo Brasileiro SATrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Petróleo Brasileiro SA — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while Petróleo Brasileiro SA trades at $17.83 (market cap $112.19B). The key difference: Petróleo Brasileiro SA is far larger — about 21.5× Crispr Therapeutics AG's market cap, and Petróleo Brasileiro SA pays a 9.42% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPPBR
Market Cap
$5.23B$112.19B
Sector
HealthTechnology
52-Week High
$76.78$22.03
52-Week Low
$44.34$11.54
Enterprise Value
$3.65B$172.61B
Dividend Yield
9.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.

Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.

Petróleo Brasileiro SA

PBR trades at $17.91, down 2.29% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a low P/E of 4.53 and robust profitability with a 24.52% net income margin. Recent Q2 2026 earnings beat expectations, with net profit nearly doubling year-over-year, driven by record production and higher oil prices (Reuters, 2026-08-06).

The investment case is supported by attractive valuations and strong cash flows, but faces headwinds from technical selling pressure and regulatory uncertainty. Analyst consensus is bullish with 50% buy ratings, though near-term price action may remain volatile amid broader market conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Petróleo Brasileiro SA

Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.

Read more on PBR